FTC consent agreement
This article was originally published in The Rose Sheet
Executive Summary
Federal Trade Commission gives final approval to a consent agreement with Thomas Fenton, a former officer or director of infomercial product Synchronal Corporation, for his role in promoting the Omexin System for Hair, a purported baldness remedy. Under the consent agreement, Fenton is prohibited from making "false and unsubstantiated" claims for any baldness treatment product, and must have scientific evidence supporting any performance claims for any food, drug or device he promotes in the future. Other provisions of the consent agreement include a prohibition on representing an ad as an independent TV program. FTC announced last June that Synchronal had agreed to pay $3.5 mil. in a proposed settlement ("The Rose Sheet" June 7, 1993, p. 1)